de Gast G C, Verdonck L F, Kreeft H A
Exp Hematol. 1985 Sep;13(8):741-4.
A total of 19 patients, treated for aggressive tumors with high-dose chemo/radiotherapy and autologous bone marrow transplantation (BMT), were studied for concanavalin-A (Con A)-induced proliferation and Con-A-induced cytotoxicity. Ten patients with cytomegalovirus (CMV) antibodies before BMT showed increased Con-A-induced cytotoxicity before and from 100 days after BMT, while Con-A-induced proliferation decreased to less than 10% of control values after BMT and remained so. Nine CMV-negative patients showed normal cytotoxic capacity before and after BMT, while Con-A-induced proliferation recovered slowly from day +30 after BMT. Con-A-induced cytotoxicity was not significantly different between CMV-positive and CMV-negative patients, while Con-A-induced proliferation showed significant differences from day +100 onward.
共有19例接受高剂量化疗/放疗及自体骨髓移植(BMT)治疗侵袭性肿瘤的患者,对其进行了刀豆球蛋白A(Con A)诱导的增殖和Con A诱导的细胞毒性研究。10例在BMT前有巨细胞病毒(CMV)抗体的患者在BMT前及BMT后100天起Con A诱导的细胞毒性增加,而Con A诱导的增殖在BMT后降至对照值的10%以下并持续如此。9例CMV阴性患者在BMT前后细胞毒性能力正常,而Con A诱导的增殖在BMT后第30天开始缓慢恢复。CMV阳性和CMV阴性患者之间Con A诱导的细胞毒性无显著差异,而Con A诱导的增殖从第100天起显示出显著差异。